TECHNOLOGY:
CoTest - Cohort Testing at the point of highest impact
AFFILIATION:
TTP, MELBOURN SG8 6EE, Select One, United Kingdom
TECHNOLOGY SUMMARY
Area:
Diagnostic technologies for identification of SARS-CoV-2 from human nasal, buccal, or saliva samples
Tech Brief: CoTest is a distributable system capable of processing pools of up to 50 saliva or UTM samples, undertaking RNA extraction on the full volume of samples whilst providing sensitivity equivalent to a single sample. CoTest is for use in high contact spaces – such as classrooms, dormitories, workplaces, airplanes.
SHOWCASE SUMMARY
Org Type:
Small to Medium Enterprise
FIGURES OF MERIT
Value Proposition: CoTest addresses the needs for both rapid action today and provides diagnostics as the first line of defense for the future. CoTest addresses an urgent need today – rapidly and accurately identifying sources of outbreak- and enabling prioritization of indivuvial testing and isolation. In the future CoTest maintains health security and monitors during support of vaccine roll-out; issues in roll-off off of effeictiveness and any risks from mutation. It is also flexible to enable introuction of testing for other viruses. Regular screening of the well in high risk environments will always be the best way to stop the spread Capture, identify and isolate immediately to: § stop spread § stop deaths § maintain economic activity Central lab testing is not economically sustainable § Logistical and staffing overhead § Turn-around time when routine screening outside of peaks likely to be slow § Some geographies cannot support central labs effectively Individual testing is highly inefficient when infection rate is low Cohort screening is a far more cost effective and sustainable solution for the long term